The Community Oncology Alliance (COA) is forging ahead with its COA Patient Advocacy Network (CPAN), says Rose Gerber, director of patient advocacy for COA. The network’s major focuses include increasing its presence and making it easier for community practices to get involved.
The Community Oncology Alliance (COA) is forging ahead with its COA Patient Advocacy Network (CPAN), says Rose Gerber, director of patient advocacy for COA. The network’s major focuses include increasing its presence and making it easier for community practices to get involved.
Transcript (slightly modified)
How do you expect COA’s Patient Advocacy Network (CPAN) to evolve?
We’ve built a fantastic foundation with CPAN. We have a national presence where we’ve partnered with a lot of national organizations. We’ve had a physical presence at state society meetings. We’ve definitely created awareness of who CPAN is. We’ve had success in building some state-based chapters at a lot of our community practices, but now to go forward, we’re referring to ourselves now as CPAN 2.0.
What we’re doing is we’re really going to embrace social media going forward. We’re going to try to standardize more events, make it easier for our practices to get involved. We do recognize that not every community practice has the resources or the bandwidth to actually start a CPAN chapter, so we’re offering many different ways for individuals to get involved in what we’ll term CPAN Light. So, there might be an opportunity for an individual to get involved, or an entire practice.
We’re really going to be pulling a lot of resources in. A very significant partnership will be with the IM Community Oncology Campaign, so as you may know, this is a very important initiative for COA, and CPAN is going to be a big part of that. It will have certain features, like we will have COA TV in a lot of our community practices. We’ll have features like the Cancer Policy Minute, and as we’re doing that, at the same time, we’ll be building our CPAN base and we’re using the term “army of advocates,” because that’s really what we’re trying to do.
What are the short-term and long-term goals for CPAN?
The short-term goal is to get more chapters involved, to really demonstrate the value, what is the value of CPAN. When I get asked that question, I say, “Your patients can be a voice for you. They can be your advocate.”
The long-term goal is to hopefully have some type of recognition in as many states as possible. Unfortunately, there’s never going to be a CPAN presence in all 50 states because there’s not community oncology in all 50 states. We’re hoping to be as inclusive as possible and to continue to grow so that every cancer survivor has the education to advocate for the preservation of community cancer care.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More